Cargando…
Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia
Daytime sleepiness is a commonly reported adverse effect associated with psychotropic agents that may impair cognitive performance and functioning. The objective of this post-hoc analysis was to evaluate the long-term effects of lurasidone and quetiapine XR on daytime sleepiness and neurocognitive p...
Autores principales: | Harvey, Philip D., Siu, Cynthia O., Loebel, Antony D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514294/ https://www.ncbi.nlm.nih.gov/pubmed/28740811 http://dx.doi.org/10.1016/j.scog.2016.05.002 |
Ejemplares similares
-
Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia
por: Loebel, Antony D., et al.
Publicado: (2013) -
PM413. Metabolic Syndrome in Patients With Schizophrenia Receiving Long-Term Treatment With Lurasidone, Quetiapine XR, or Risperidone
por: Newcomer, John W., et al.
Publicado: (2016) -
Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
por: Restelli, Umberto, et al.
Publicado: (2020) -
Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis
por: Newcomer, John W., et al.
Publicado: (2018) -
F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE
por: Pikalov, Andrei, et al.
Publicado: (2018)